Company Filing History:
Years Active: 1976
Title: Inventor Spotlight: David Lawrence Gravett
Introduction: David Lawrence Gravett, based in Amersham, GB, is a notable inventor recognized for his contributions to the field of medical diagnostics. His innovative work has paved the way for advancements in the use of radioactive labeled-fibrinogen and its applications in thrombus diagnosis.
Latest Patents: Gravett holds a patent for a composition that comprises radioactive labeled-fibrinogen and albumin. The key aspect of this invention is the stability of fibrinogen, which is enhanced by the incorporation of albumin, preferably in a ratio of at least five parts by weight of albumin to one part by weight of fibrinogen. This unique composition enables the iodinated (.sup.125 I) human fibrinogen to be stabilized with human serum albumin, thereby improving its efficacy in diagnosing thrombi.
Career Highlights: David Lawrence Gravett's career at The Radiochemical Centre Limited has been marked by significant contributions to the field of radiochemistry and medical diagnostics. His innovative approach has led to the successful development of novel solutions that address critical medical challenges.
Collaborations: Throughout his career, Gravett has collaborated with various experts, including notable colleague John C. Charlton. Their combined efforts have advanced the understanding and application of radiochemical compounds in medicine, highlighting the importance of teamwork in driving innovation.
Conclusion: David Lawrence Gravett exemplifies the role of inventors in transforming complex scientific concepts into practical applications. His work not only enhances the stability of essential compounds but also significantly impacts medical diagnostics, showcasing the vital interplay between innovation and healthcare.